FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3098416691> ?p ?o ?g. }

• W3098416691 abstract "Background CDX-1140 is an agonist anti-CD40 mAb selected to optimize systemic exposure and hence tumor microenvironment (TME) ingress. CDX-1140 activity may be enhanced by combining with CDX-301 (recombinant Flt3L), a dendritic cell growth factor, or with pembrolizumab, an anti-PD-1 mAb. Methods Patients with advanced solid or hematologic (Part 1 only) tumors are enrolled. Part 1 dose-escalation results have been presented (SITC 2019). In Part 2, CDX-1140 dose-escalation (0.09–1.5 mg/kg q4w) is in combination with CDX-301 (75 mcg/kg sc QD x 5 for 2 cycles). In Part 3, CDX-1140 dose-escalation (0.72–1.5 mg/kg q3w) is in combination with pembrolizumab 200 mg q3w. Part 1 and 2 expansion cohorts are dosed at the CDX-1140 MTD, 1.5 mg/kg q4w. Part 3 expansion cohorts are planned. Peripheral blood and tumor biomarkers analysis are ongoing. Results 92 patients have been treated (Part 1 n=57, Part 2 n=31, Part 3 n=4). Part 1 expansion cohorts in SCCHN (n=7) and RCC (n=5) are fully enrolled. Part 2 dose-escalation completed to the highest CDX-1140 dose and a SCCHN expansion cohort is ongoing. Part 3 dose-escalation recently initiated. Safety data is available for 23 and 10 patients at the MTD in Part 1 and 2, respectively. In general, the safety profiles were similar, with arthralgia (52% vs. 50%), pyrexia (44% vs 50%), fatigue (30% vs. 50%), chills (39% vs. 40%), vomiting (30% vs. 20%), nausea (26% vs 40%), myalgia (22% vs. 30%), increased ALT (22% vs. 20%), and increased AST (22% vs. 30%) being the most common drug related AEs at the MTD in Part 1 and 2, respectively. Most AEs were low grade. Across all cohorts, cytokine release syndrome (CRS) (G2 n=4, G3 n=2) occurred in 6 (Part 1 n=2; Part 2 n=4) and pneumonitis (G3) occurred in 5 (Part 1 n=4; Part 2 n=1) patients. Immune activation in the TME consistent with CD40 agonism and increases serum inflammatory cytokines were observed. Evidence of anti-tumor activity/clinical benefit include SD (n=13), tumor cavitation (n=2) and a uPR in solid tumors. A patient with follicular lymphoma has an ongoing durable complete metabolic response. Conclusions The CDX-1140 MTD dose of 1.5 mg/kg, a dose level expected to provide good systemic exposure and TME penetration, is generally well tolerated alone and with CDX-301. Transaminitis and CRS have generally been low grade and infrequent. A cohort combining CDX-1140 with chemotherapy will be initiated in patients with previously untreated metastatic pancreatic adenocarcinoma. Trial Registration NCT03329950 Ethics Approval The study was approved by the following: Providence St. Joseph Health IRB, approval number MOD2020001128; WIRB, approval number 1188814 (Hauke, Gabrail, Bordoni & Gordon); University of Pennsylvania IRB, approval number UPCC 18917; Mount Sinai School of Medicine IRB, approval number 18-00202; Memorial Sloan Kettering Cancer Center IRB, approval number 18-225A; Houston Methodist IRB, approval number MOD00000836" @default.
• W3098416691 created "2020-11-23" @default.
• W3098416691 creator A5001193982 @default.
• W3098416691 creator A5005462156 @default.
• W3098416691 creator A5014236598 @default.
• W3098416691 creator A5020755903 @default.
• W3098416691 creator A5028465682 @default.
• W3098416691 creator A5035148529 @default.
• W3098416691 creator A5042029338 @default.
• W3098416691 creator A5043668012 @default.
• W3098416691 creator A5055358847 @default.
• W3098416691 creator A5057343975 @default.
• W3098416691 creator A5062558399 @default.
• W3098416691 creator A5066367673 @default.
• W3098416691 creator A5069690249 @default.
• W3098416691 creator A5072567296 @default.
• W3098416691 creator A5074279762 @default.
• W3098416691 creator A5077196075 @default.
• W3098416691 creator A5082283453 @default.
• W3098416691 creator A5088223962 @default.
• W3098416691 date "2020-11-01" @default.
• W3098416691 modified "2023-09-23" @default.
• W3098416691 title "405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)" @default.
• W3098416691 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0405" @default.
• W3098416691 hasPublicationYear "2020" @default.
• W3098416691 type Work @default.
• W3098416691 sameAs 3098416691 @default.
• W3098416691 citedByCount "3" @default.
• W3098416691 countsByYear W30984166912021 @default.
• W3098416691 countsByYear W30984166912022 @default.
• W3098416691 countsByYear W30984166912023 @default.
• W3098416691 crossrefType "proceedings-article" @default.
• W3098416691 hasAuthorship W3098416691A5001193982 @default.
• W3098416691 hasAuthorship W3098416691A5005462156 @default.
• W3098416691 hasAuthorship W3098416691A5014236598 @default.
• W3098416691 hasAuthorship W3098416691A5020755903 @default.
• W3098416691 hasAuthorship W3098416691A5028465682 @default.
• W3098416691 hasAuthorship W3098416691A5035148529 @default.
• W3098416691 hasAuthorship W3098416691A5042029338 @default.
• W3098416691 hasAuthorship W3098416691A5043668012 @default.
• W3098416691 hasAuthorship W3098416691A5055358847 @default.
• W3098416691 hasAuthorship W3098416691A5057343975 @default.
• W3098416691 hasAuthorship W3098416691A5062558399 @default.
• W3098416691 hasAuthorship W3098416691A5066367673 @default.
• W3098416691 hasAuthorship W3098416691A5069690249 @default.
• W3098416691 hasAuthorship W3098416691A5072567296 @default.
• W3098416691 hasAuthorship W3098416691A5074279762 @default.
• W3098416691 hasAuthorship W3098416691A5077196075 @default.
• W3098416691 hasAuthorship W3098416691A5082283453 @default.
• W3098416691 hasAuthorship W3098416691A5088223962 @default.
• W3098416691 hasConcept C121608353 @default.
• W3098416691 hasConcept C126322002 @default.
• W3098416691 hasConcept C143998085 @default.
• W3098416691 hasConcept C197934379 @default.
• W3098416691 hasConcept C2777701055 @default.
• W3098416691 hasConcept C2778594517 @default.
• W3098416691 hasConcept C2780057760 @default.
• W3098416691 hasConcept C2780852908 @default.
• W3098416691 hasConcept C71924100 @default.
• W3098416691 hasConcept C90924648 @default.
• W3098416691 hasConceptScore W3098416691C121608353 @default.
• W3098416691 hasConceptScore W3098416691C126322002 @default.
• W3098416691 hasConceptScore W3098416691C143998085 @default.
• W3098416691 hasConceptScore W3098416691C197934379 @default.
• W3098416691 hasConceptScore W3098416691C2777701055 @default.
• W3098416691 hasConceptScore W3098416691C2778594517 @default.
• W3098416691 hasConceptScore W3098416691C2780057760 @default.
• W3098416691 hasConceptScore W3098416691C2780852908 @default.
• W3098416691 hasConceptScore W3098416691C71924100 @default.
• W3098416691 hasConceptScore W3098416691C90924648 @default.
• W3098416691 hasLocation W30984166911 @default.
• W3098416691 hasOpenAccess W3098416691 @default.
• W3098416691 hasPrimaryLocation W30984166911 @default.
• W3098416691 hasRelatedWork W2524976195 @default.
• W3098416691 hasRelatedWork W2748952813 @default.
• W3098416691 hasRelatedWork W2792600153 @default.
• W3098416691 hasRelatedWork W2899084033 @default.
• W3098416691 hasRelatedWork W2948845624 @default.
• W3098416691 hasRelatedWork W3021169115 @default.
• W3098416691 hasRelatedWork W3082907133 @default.
• W3098416691 hasRelatedWork W3159448218 @default.
• W3098416691 hasRelatedWork W3205930903 @default.
• W3098416691 hasRelatedWork W4221123017 @default.
• W3098416691 isParatext "false" @default.
• W3098416691 isRetracted "false" @default.
• W3098416691 magId "3098416691" @default.
• W3098416691 workType "article" @default.